[{"id":"239cfbfd-4502-4f5e-a5da-4b96cfe72590","acronym":"","url":"https://clinicaltrials.gov/study/NCT07498400","created_at":"2026-04-04T01:40:42.252Z","updated_at":"2026-04-04T01:40:42.252Z","phase":"","brief_title":"Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer","source_id_and_acronym":"NCT07498400","lead_sponsor":"Xijing Hospital","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 216","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2026-03-27"},{"id":"15523e72-2092-4615-84e9-c8dac7362a0e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07484087","created_at":"2026-03-28T01:36:33.328Z","updated_at":"2026-03-28T01:36:33.328Z","phase":"","brief_title":"Ablation Compare With Surgery for Early Breast Cancer","source_id_and_acronym":"NCT07484087","lead_sponsor":"Peking University People's Hospital","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • HER-2 negative + AR positive + ER positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 negative + AR positive + ER positive"],"overall_status":"Recruiting","enrollment":" Enrollment 264","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2031","study_completion_date":" 12/31/2031","last_update_posted":"2026-03-19"},{"id":"b06c4a15-488d-4c26-b536-d32ff1360c20","acronym":"EINSTEIN-TNBC","url":"https://clinicaltrials.gov/study/NCT07478705","created_at":"2026-03-28T01:41:18.017Z","updated_at":"2026-03-28T01:41:18.017Z","phase":"","brief_title":"Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid Biopsy and Imaging","source_id_and_acronym":"NCT07478705 - EINSTEIN-TNBC","lead_sponsor":"Sunnybrook Health Sciences Centre","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2026","start_date":" 05/01/2026","primary_txt":" Primary completion: 05/01/2029","primary_completion_date":" 05/01/2029","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2026-03-17"},{"id":"503fb49c-7f9c-44d3-9d06-e13901c0cc31","acronym":"","url":"https://clinicaltrials.gov/study/NCT07471815","created_at":"2026-03-28T01:43:58.232Z","updated_at":"2026-03-28T01:43:58.232Z","phase":"Phase 2","brief_title":"Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy","source_id_and_acronym":"NCT07471815","lead_sponsor":"Harbin Medical University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/04/2026","start_date":" 03/04/2026","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2029","study_completion_date":" 03/31/2029","last_update_posted":"2026-03-13"},{"id":"640bd8bb-4222-4e6d-9561-db85c94d3a6d","acronym":"RELAX","url":"https://clinicaltrials.gov/study/NCT07469267","created_at":"2026-03-28T01:43:25.428Z","updated_at":"2026-03-28T01:43:25.428Z","phase":"","brief_title":"Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases","source_id_and_acronym":"NCT07469267 - RELAX","lead_sponsor":"Fudan University","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 1608","initiation":"Initiation: 10/24/2025","start_date":" 10/24/2025","primary_txt":" Primary completion: 12/31/2032","primary_completion_date":" 12/31/2032","study_txt":" Completion: 12/31/2035","study_completion_date":" 12/31/2035","last_update_posted":"2026-03-13"},{"id":"68ed3b37-b467-4c04-902f-70c0e053d74f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02945579","created_at":"2021-01-18T14:27:45.395Z","updated_at":"2025-02-25T12:26:33.859Z","phase":"","brief_title":"Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy","source_id_and_acronym":"NCT02945579","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PGR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/20/2017","start_date":" 01/20/2017","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-02-24"},{"id":"74157a34-d6de-4ba9-9962-025f2effcf7f","acronym":"ALPHABET","url":"https://clinicaltrials.gov/study/NCT05063786","created_at":"2021-10-01T11:54:26.039Z","updated_at":"2025-02-25T12:37:59.796Z","phase":"Phase 3","brief_title":"Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)","source_id_and_acronym":"NCT05063786 - ALPHABET","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" HER-2 • ER • PIK3CA • PGR","pipe":" | ","alterations":" ER positive • PIK3CA mutation","tags":["HER-2 • ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • capecitabine • Piqray (alpelisib) • fulvestrant • Halaven (eribulin mesylate) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-24"},{"id":"7b820269-141f-4024-866b-63f1d5de0853","acronym":"S2206","url":"https://clinicaltrials.gov/study/NCT06058377","created_at":"2023-09-28T14:10:22.699Z","updated_at":"2025-02-25T12:29:51.382Z","phase":"Phase 3","brief_title":"Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer","source_id_and_acronym":"NCT06058377 - S2206","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • daunorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 3680","initiation":"Initiation: 11/27/2023","start_date":" 11/27/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2025-02-24"},{"id":"e5a7e816-2338-4069-ab5a-d3e2d67f258f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04243616","created_at":"2021-01-18T20:37:50.114Z","updated_at":"2025-02-25T12:27:27.130Z","phase":"Phase 2","brief_title":"Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer","source_id_and_acronym":"NCT04243616","lead_sponsor":"Medical College of Wisconsin","biomarkers":" HER-2 • PD-L1 • PGR • PD-L2","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • PGR positive","tags":["HER-2 • PD-L1 • PGR • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel • cyclophosphamide • pegylated liposomal doxorubicin • Libtayo (cemiplimab-rwlc) • cyclophosphamide intravenous • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/05/2020","start_date":" 03/05/2020","primary_txt":" Primary completion: 07/14/2025","primary_completion_date":" 07/14/2025","study_txt":" Completion: 08/13/2025","study_completion_date":" 08/13/2025","last_update_posted":"2025-02-24"},{"id":"e892208a-36f9-4d6f-a38c-e7cd64d31bd9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03659136","created_at":"2021-01-18T17:57:27.537Z","updated_at":"2025-02-25T12:26:58.565Z","phase":"Phase 2","brief_title":"The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread","source_id_and_acronym":"NCT03659136","lead_sponsor":"Boehringer Ingelheim","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • exemestane • xentuzumab (BI-836845)"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 11/28/2018","start_date":" 11/28/2018","primary_txt":" Primary completion: 08/30/2021","primary_completion_date":" 08/30/2021","study_txt":" Completion: 05/11/2022","study_completion_date":" 05/11/2022","last_update_posted":"2025-02-24"},{"id":"1ee7d622-cdd0-4c14-a5ad-ff67b7a251a6","acronym":"NCI-2021-11793","url":"https://clinicaltrials.gov/study/NCT05111561","created_at":"2021-11-08T14:53:11.471Z","updated_at":"2025-02-25T13:40:41.596Z","phase":"Phase 1","brief_title":"Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer","source_id_and_acronym":"NCT05111561 - NCI-2021-11793","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS • BRAF • ER • PGR • NRAS • HRAS • NF1","pipe":" | ","alterations":" BRAF mutation • HER-2 amplification • HRAS mutation • BRAF fusion","tags":["HER-2 • KRAS • BRAF • ER • PGR • NRAS • HRAS • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • HER-2 amplification • HRAS mutation • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • ZEN-3694"],"overall_status":"Suspended","enrollment":" Enrollment 42","initiation":"Initiation: 08/02/2022","start_date":" 08/02/2022","primary_txt":" Primary completion: 03/14/2025","primary_completion_date":" 03/14/2025","study_txt":" Completion: 03/14/2025","study_completion_date":" 03/14/2025","last_update_posted":"2025-02-21"},{"id":"44d24989-a21f-4511-a498-f631f60a4181","acronym":"","url":"https://clinicaltrials.gov/study/NCT03554109","created_at":"2021-01-18T17:29:18.298Z","updated_at":"2025-02-25T13:39:37.796Z","phase":"Phase 2","brief_title":"QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine","source_id_and_acronym":"NCT03554109","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Bavencio (avelumab) • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061 • GI-4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2018","start_date":" 09/01/2018","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 02/09/2022","study_completion_date":" 02/09/2022","last_update_posted":"2025-02-21"},{"id":"9533b278-204e-4b79-a649-08a89f8bf87b","acronym":"HeNRIetta","url":"https://clinicaltrials.gov/study/NCT02515110","created_at":"2021-01-18T12:09:11.616Z","updated_at":"2025-02-25T13:39:18.041Z","phase":"","brief_title":"Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer","source_id_and_acronym":"NCT02515110 - HeNRIetta","lead_sponsor":"Virginia Commonwealth University","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 137","initiation":"Initiation: 08/04/2015","start_date":" 08/04/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-21"},{"id":"9563a22f-1431-499b-ba51-cc38d3b74ea7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04345913","created_at":"2021-01-18T21:01:42.609Z","updated_at":"2025-02-25T13:40:07.851Z","phase":"Phase 1/2","brief_title":"Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT04345913","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PIK3CA • PGR • PTEN","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • PIK3CA mutation","tags":["ER • PIK3CA • PGR • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-21"},{"id":"c28173c9-ac67-4f97-95aa-85bf990befb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04052555","created_at":"2021-01-18T19:52:14.840Z","updated_at":"2025-02-25T13:39:55.670Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT04052555","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 09/24/2020","start_date":" 09/24/2020","primary_txt":" Primary completion: 11/20/2025","primary_completion_date":" 11/20/2025","study_txt":" Completion: 11/20/2025","study_completion_date":" 11/20/2025","last_update_posted":"2025-02-21"},{"id":"11ed08db-6adc-4dff-97ee-d51d291166de","acronym":"TRACERX-TNBC","url":"https://clinicaltrials.gov/study/NCT03077776","created_at":"2021-01-18T15:09:42.996Z","updated_at":"2025-02-25T13:52:16.877Z","phase":"","brief_title":"Tracking Triple-negative Breast Cancer Evolution Through Therapy","source_id_and_acronym":"NCT03077776 - TRACERX-TNBC","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 149","initiation":"Initiation: 04/14/2017","start_date":" 04/14/2017","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-20"},{"id":"5eb63239-f0c2-440d-925c-994f2877adc9","acronym":"","url":"https://clinicaltrials.gov/study/NCT00740805","created_at":"2021-01-18T02:47:51.919Z","updated_at":"2025-02-25T13:47:58.987Z","phase":"Phase 1","brief_title":"Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT00740805","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA","pipe":" | ","alterations":" HER-2 negative • BRCA mutation","tags":["HER-2 • ER • PGR • BRCA1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • veliparib (ABT-888) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 08/18/2008","start_date":" 08/18/2008","primary_txt":" Primary completion: 09/03/2021","primary_completion_date":" 09/03/2021","study_txt":" Completion: 10/22/2025","study_completion_date":" 10/22/2025","last_update_posted":"2025-02-20"},{"id":"59306281-9d17-43db-95fc-ecad547b1392","acronym":"","url":"https://clinicaltrials.gov/study/NCT05719558","created_at":"2023-02-09T16:00:40.694Z","updated_at":"2025-02-25T14:03:18.450Z","phase":"Phase 1","brief_title":"A Study of ASP1002 in Adults for Treatment of Solid Tumors","source_id_and_acronym":"NCT05719558","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ASP1002"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 03/13/2023","start_date":" 03/13/2023","primary_txt":" Primary completion: 04/30/2028","primary_completion_date":" 04/30/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-02-19"},{"id":"91477ff8-142f-4402-9532-82ad52403fb8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03804944","created_at":"2021-01-18T18:48:24.995Z","updated_at":"2025-02-25T14:01:36.868Z","phase":"Phase 2","brief_title":"Converting HR+ Breast Cancer Into an Individualized Vaccine","source_id_and_acronym":"NCT03804944","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Mobista (CDX-301)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/17/2020","start_date":" 03/17/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-19"},{"id":"be1e3182-1b8c-4aa1-8e6a-90c8411f7afc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05996107","created_at":"2023-08-16T16:08:40.965Z","updated_at":"2025-02-25T14:03:44.386Z","phase":"Phase 1","brief_title":"Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT05996107","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/27/2024","start_date":" 02/27/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2030","study_completion_date":" 06/01/2030","last_update_posted":"2025-02-19"},{"id":"e1eec305-12a1-4b55-aca1-9621bccaf5e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05836324","created_at":"2023-05-01T15:04:34.613Z","updated_at":"2025-02-25T14:03:30.395Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05836324","lead_sponsor":"Incyte Corporation","biomarkers":" HER-2 • BRAF • ER • PGR • ROS1","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["HER-2 • BRAF • ER • PGR • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INCA33890"],"overall_status":"Recruiting","enrollment":" Enrollment 245","initiation":"Initiation: 07/24/2023","start_date":" 07/24/2023","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2026","study_completion_date":" 12/24/2026","last_update_posted":"2025-02-19"},{"id":"e34a5a55-d8a1-4469-8532-07c6096c4f21","acronym":"KELLY","url":"https://clinicaltrials.gov/study/NCT03222856","created_at":"2021-01-18T15:54:23.632Z","updated_at":"2025-02-25T14:01:19.405Z","phase":"Phase 2","brief_title":"Ph II Study of Pembrolizumab \u0026 Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines \u0026 Taxanes","source_id_and_acronym":"NCT03222856 - KELLY","lead_sponsor":"MedSIR","biomarkers":" HER-2 • PD-L1 • ER • PGR • TMB","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Halaven (eribulin mesylate)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 12/14/2017","start_date":" 12/14/2017","primary_txt":" Primary completion: 10/31/2018","primary_completion_date":" 10/31/2018","study_txt":" Completion: 12/23/2020","study_completion_date":" 12/23/2020","last_update_posted":"2025-02-19"},{"id":"48f5abe6-9ec9-4e35-ad4a-60d366e60af6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03598257","created_at":"2021-01-18T17:41:27.688Z","updated_at":"2025-02-25T14:15:11.919Z","phase":"Phase 2","brief_title":"Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer","source_id_and_acronym":"NCT03598257","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 01/18/2019","start_date":" 01/18/2019","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-17"},{"id":"dc906474-83f8-4b00-bb2c-8553f48dae62","acronym":"","url":"https://clinicaltrials.gov/study/NCT03624543","created_at":"2021-01-18T17:48:24.810Z","updated_at":"2025-02-25T14:07:13.959Z","phase":"Phase 2","brief_title":"CFI-400945 in Patients With Advanced/Metastatic Breast Cancer","source_id_and_acronym":"NCT03624543","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" HER-2 • PGR • PTEN","pipe":" | ","alterations":" PTEN mutation","tags":["HER-2 • PGR • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ocifisertib (CFI-400945)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 02/14/2019","start_date":" 02/14/2019","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-17"}]